Skip to main content
. 2018 Jan 19;103(5):840–848. doi: 10.3324/haematol.2017.180554

Figure 3.

Figure 3.

Response after ruxolitinib. Illustrative patient (UPN 601001). Comparison of frontal positron emission tomography (PET)-scan prior to inclusion and after 2 months of ruxolitinib. There was a rapid improvement of constitutional symptoms after a few days on ruxolitinib. PET after 2 months showed metabolic partial response with a total volume reduction of tumor lung lesions of 64%.